Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer’s disease
暂无分享,去创建一个
A. Lleó | J. Fortea | D. Alcolea | Marina Canyelles | M. Tondo | J. Arranz | Soraya Torres | S. Rubio-Guerra | Shaimaa El Bounasri | Rosa Ferrer | N. Zhu | Oriol Sánchez | Í. Rodríguez-Baz | Andrea Mansilla | M. Canyelles
[1] M. Plebani,et al. Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer’s disease , 2022, Clinical chemistry and laboratory medicine.
[2] M. Carrillo,et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[3] K. Blennow,et al. Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease , 2022, Alzheimer's research & therapy.
[4] A. Lleó,et al. Importance of cerebrospinal fluid storage conditions for the Alzheimer’s disease diagnostics on an automated platform , 2022, Clinical chemistry and laboratory medicine.
[5] K. Blennow,et al. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[6] T. Vos,et al. The estimation of the global prevalence of dementia from 1990‐2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019 , 2021, Alzheimer's & Dementia.
[7] K. Blennow,et al. Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[8] K. Blennow,et al. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease , 2021, JAMA neurology.
[9] James G. Bollinger,et al. The global Alzheimer's Association round robin study on plasma amyloid β methods , 2021, Alzheimer's & dementia.
[10] K. Blennow,et al. Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration , 2021, Alzheimer's & dementia.
[11] Pei-Ning Wang,et al. Effect of Times to Blood Processing on the Stability of Blood Proteins Associated with Dementia , 2020, Dementia and Geriatric Cognitive Disorders.
[12] M. Chiu,et al. Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles , 2020, Dementia and Geriatric Cognitive Disorders Extra.
[13] L. Goldstein,et al. Amyloid-β-independent regulators of tau pathology in Alzheimer disease , 2019, Nature Reviews Neuroscience.
[14] Amanda Jiménez,et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders , 2019, Alzheimer's & dementia.
[15] R. Batrla,et al. Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers , 2019, Alzheimer's & dementia.
[16] J. Schott,et al. Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles , 2018, Alzheimer's & dementia.
[17] A. Fagan,et al. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review , 2018, Alzheimer's & Dementia.
[18] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[19] Linda J. C. van Waalwijk van Doorn,et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[20] Magda Tsolaki,et al. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases , 2015, Nature Reviews Neurology.
[21] K. Blennow. Dementia in 2010: Paving the way for Alzheimer disease drug development , 2011, Nature Reviews Neurology.